跳至主要内容
临床试验/IRCT2016070628814N1
IRCT2016070628814N1已完成2 期

The effect of addition of enoxaparin to neoadjuvant chemoradiation of esophageal cancer on the clinical and pathologic response and value of post-chemoradiation findings in prediction of complete pathologic response

Vice chancellor for research, Mashhad University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Inclusion criteria are definitive diagnoses of esophageal cancer by oncologist and pathological evaluation, non-metastatic esophageal cancer, patient who are candidate for chemo-radiation treatment, pathological report of SCC, normal CBC, normal kidney function test, normal liver function test, normal FBS.
  • Exclusion criteria are previous history of chest wall radiotherapy, previous history of chemotherapy, past medical history of HTN, DM, renal failure and liver failure, pathological report of adenocarcinoma or small cell carcinoma, neoplasm of other organs, discontent for the study, inability to do daily radiotherapy, unwillingness to esophagectomy.

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Mashhad University of Medical Sciences

相似试验